Q-omics provides the consensus-scored HSH2D profile across patient tissues and cancer cell-line models. HSH2D expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, HSH2D is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, HSH2D RNA expression shows 17,686 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, LUAD, and LSCC as cancer lineages where HSH2D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSH2D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSH2D survival associations across molecular data types. HSH2D RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSH2D RNA expression–survival associations across cancer types. High HSH2D expression shows unfavorable associations in ACC and KIRC, but favorable associations in BLCA, SKCM, HNSC and MESO. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for HSH2D RNA expression.
This table summarizes HSH2D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for HSH2D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSH2D shows lower tumor expression in LUSC and higher tumor expression in LUAD, STAD, BRCA, COAD and CHOL. The LUAD box plot shows higher HSH2D RNA expression in tumor versus normal tissue (log2 FC = +1.262, t-test p < 0.001).
This table shows molecular features associated with HSH2D in patient tissues and cancer cell lines. In patient samples, HSH2D shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HSH2D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LUNG_NSCLC_LUSC.
